Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 4/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | NCOA2 | Q15596 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3347072 | 0.85 | GSK3B (0.59) | GSK3BPOLBRXFP1ALDH1A1HPGD | |
| SCHEMBL9879027 | 0.83 | GSK3B (0.58) | GSK3BPOLBRXFP1ALDH1A1HPGD | |
| SCHEMBL14157094 | 0.83 | POLB (0.50) | LMNAPOLBALDH1A1HPGDMEN1 | |
| SCHEMBL5206235 | 0.83 | GSK3B (0.50) | GSK3BLMNATSHRPOLBRXFP1 | |
| SCHEMBL9879032 | 0.82 | GSK3B (0.56) | GSK3BPOLBRXFP1ALDH1A1HPGD | |
| SCHEMBL5749082 | 0.81 | ALDH1A1 (0.55) | GSK3BPOLBALDH1A1HPGDNPSR1 | |
| SCHEMBL7433029 | 0.81 | HPGD (0.49) | LMNATSHRPOLBALDH1A1HPGD | |
| SCHEMBL64687 | 0.80 | HDAC3 (0.58) | GSK3BLMNATSHRPOLBRXFP1 | |
| SCHEMBL3958438 | 0.78 | HDAC3 (0.57) | GSK3BLMNATSHRPOLBRXFP1 | |
| SCHEMBL14624168 | 0.78 | GSK3B (0.63) | GSK3BPOLBRXFP1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822945-B1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B V (NL) | 2019-06-19 | — | — | EP | disclosed |
| US-10071987-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2018-09-11 | — | — | US | disclosed |
| US-20180030035-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2018-02-01 | — | — | US | disclosed |
| US-9790205-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2017-10-17 | — | — | US | disclosed |
| EP-3220435-A1 | ORGANIC SEMICONDUCTOR ELEMENT AND COMPOUND | Fujifilm Corporation (JP) | 2017-09-20 | — | — | EP | disclosed |
| US-20170240531-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2017-08-24 | — | — | US | disclosed |
| US-20170229655-A1 | ORGANIC SEMICONDUCTOR ELEMENT, MANUFACTURING METHOD THEREOF, COMPOUND, COMPOSITION FOR FORMING ORGANIC SEMICONDUCTOR FILM, AND ORGANIC SEMICONDUCTOR FILM | FUJIFILM CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-20170229655-A1 | ORGANIC SEMICONDUCTOR ELEMENT, MANUFACTURING METHOD THEREOF, COMPOUND, COMPOSITION FOR FORMING ORGANIC SEMICONDUCTOR FILM, AND ORGANIC SEMICONDUCTOR FILM | FUJIFILM CORPORATION (JP) | 2017-08-10 | — | — | US | disclosed |
| US-9676764-B2 | Aminomethylene pyrazolones with therapeutic activity | COMPOUND HANDLING B.V. (NL) | 2017-06-13 | — | — | US | disclosed |
| US-20160326152-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | COMPOUND HANDLING B.V. (NL) | 2016-11-10 | — | — | US | disclosed |
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| US-8106046-B2 | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-01-31 | — | — | US | disclosed |
| CN-102149710-A | Cyclopentathiophene modulators of the glucocorticoid receptor, AP-1, and/or NF-Kappa B activity and use thereof | BRISTOL MYERS SQUIBB CO | 2011-08-10 | — | — | CN | disclosed |
| EP-2334671-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | Bristol-Myers Squibb Company (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| WO-2009158380-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009158380-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPA B ACTIVITY AND USE THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180030035-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | GSK3B 3600/4885LMNA 1368/4885TSHR 194/4885 |
| US-20110105495-A1 | CYCLOPENTATHIOPHENE MODULATORS OF THE GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF | NFKB2, NFKB1, NFRKB | GSK3B 973/4885LMNA 4657/4885TSHR 795/4885 |
| US-10071987-B2 | Aminomethylene pyrazolones with therapeutic activity | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | GSK3B 3600/4885LMNA 1368/4885TSHR 194/4885 |
| US-20170240531-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | GSK3B 3608/4885LMNA 1320/4885TSHR 206/4885 |
| US-20160326152-A1 | AMINOMETHYLENE PYRAZOLONES WITH THERAPEUTIC ACTIVITY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA3, CBR3 | GSK3B 3608/4885LMNA 1320/4885TSHR 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.